Fulzerasib vs Sotorasib

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Non-Small Cell Lung Cancer

Shared mechanism: KRAS G12C · full Non-Small Cell Lung Cancer pipeline

Fulzerasib · Dupert

Marketed by Innovent Biologics under a licence from GenFleet Therapeutics

Phase 2 in Non-Small Cell Lung Cancersmall molecule
Weak signal

NCT05756153 · Phase 1/2 · completed

KROCUS was a single-arm, open-label Phase 1b/2 trial of fulzerasib plus cetuximab in previously untreated KRAS G12C-mutated non-small-cell lung cancer, with 47 patients treated at 30 centres. The Phase 2 primary endpoint was the investigator-assessed objective response rate, and the confirmed rate was 69% (90% CI 56 to 80). With no comparator arm and no formal success threshold reported, no result can be called met or missed. Treatment-related adverse events occurred in 87% of patients, grade 3 in 15%, with no grade 4 or 5 events. The figures come from the final peer-reviewed report (Gregorc et al., Lancet Oncol 2026).

Single-arm response rate with no comparator and no formal statistical threshold.

Next expected readout: March 2027 · NCT07492342 (registry estimate)

Reported efficacy

Phase Ib: adverse events (28 days); Phase II: objective response rate (up to 1 year after last patient in): Confirmed investigator-assessed objective response rate per RECIST 1.1 (Phase 2 primary), fulzerasib 600 mg twice daily plus cetuximab, single arm, first-line KRAS G12C NSCLC: 69% (90% CI 56 to 80); 47 patients treated; data cutoff 14 January 2025. (not_applicable)

Result source: NCT05756153

Sotorasib

Marketed by Amgen and partners

Approved in Non-Small Cell Lung Cancersmall molecule
Partial signal

NCT04303780 · Phase 3 · completed

The 345 participants were randomized 1:1 to sotorasib or active-comparator docetaxel, but treatment assignment was not masked. The primary clinical endpoint, progression-free survival assessed by blinded independent central review, was met in favor of sotorasib, with median progression-free survival of 5.62 versus 4.47 months and a hazard ratio of 0.663 (p=0.002).

Next expected readout: November 2026 · NCT06249282 (registry estimate)

Reported efficacy

Progression-free Survival (PFS) (Baseline up to primary analysis data cut-off date (02 August 2022); max time on study as of primary analysis data cut off was 24.3 months): Progression-free Survival (PFS) (Baseline up to primary analysis data cut-off date (02 August 2022); max time on study as of primary analysis data cut off was 24.3 months): AMG 510 5.62 months (95% CI 4.27 to 7.75) vs Docetaxel 4.47 months (95% CI 3.02 to 5.68) (met)

Result source: NCT04303780

Results for Non-Small Cell Lung Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointFulzerasibSotorasib
PFS, median—Trial running · NCT076010485.6 vs 4.5vs Docetaxeln 171NCT04303780
2 other results
  • 7.7 200 mg BIW D1D2 + 960 mg QD · n 43 · Phase 2 · secondary NCT05054725
  • 2.6 140 mg BIW D1D2 + 960 mg QD · n 4 · Phase 2 · secondary NCT05054725
OS, median—Trial running · NCT0760104812.4b200 mg BIW D1D2 + 960 mg QD · n 43NCT05054725
1 other result
  • 5.8 140 mg BIW D1D2 + 960 mg QD · n 4 · Phase 2 · secondary NCT05054725
ORR—Trial running · NCT07601048—Trial running · NCT06497556
Duration of response, median—Trial running · NCT0760104812.2b200 mg BIW D1D2 + 960 mg QD · n 11NCT05054725

PFS, median

Fulzerasib
—Trial running · NCT07601048
Sotorasib
5.6 vs 4.5vs Docetaxeln 171NCT04303780
2 other results
  • 7.7 200 mg BIW D1D2 + 960 mg QD · n 43 · Phase 2 · secondary NCT05054725
  • 2.6 140 mg BIW D1D2 + 960 mg QD · n 4 · Phase 2 · secondary NCT05054725

OS, median

Fulzerasib
—Trial running · NCT07601048
Sotorasib
12.4b200 mg BIW D1D2 + 960 mg QD · n 43NCT05054725
1 other result
  • 5.8 140 mg BIW D1D2 + 960 mg QD · n 4 · Phase 2 · secondary NCT05054725

ORR

Fulzerasib
—Trial running · NCT07601048
Sotorasib
—Trial running · NCT06497556

Duration of response, median

Fulzerasib
—Trial running · NCT07601048
Sotorasib
12.2b200 mg BIW D1D2 + 960 mg QD · n 11NCT05054725
  1. b Single-arm result: the trial had no control arm, so the number has no comparator and does not compare with a randomised result.
  2. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  3. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Fulzerasib
Confirmed investigator-assessed objective response rate per RECIST 1.1 (Phase 2 primary), fulzerasib 600 mg twice daily plus cetuximab, single arm, first-line KRAS G12C NSCLC: 69% (90% CI 56 to 80); 47 patients treated; data cutoff 14 January 2025. NCT05756153 · Phase 1/2 · design grade: weak · publication or press release

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Fulzerasib: 0 of 4 rows · Sotorasib: 3 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricSotorasib
Dropout rate
100%a
NCT04303780 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 3 more results
—200 mg BIW D1D2 + 960 mg QD
NCT05054725 · Phase 2 · registry result, not featured evidence · combination
93%200 mg D1D2 + 960 mg QD
NCT05054725 · Phase 2 · registry result, not featured evidence · combination
100%140 mg BIW D1D2 + 960 mg QD
NCT05054725 · Phase 2 · registry result, not featured evidence · combination
Discontinued due to AEs
—a
NCT04303780 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 3 more results
—200 mg BIW D1D2 + 960 mg QD
NCT05054725 · Phase 2 · registry result, not featured evidence · combination
—200 mg D1D2 + 960 mg QD
NCT05054725 · Phase 2 · registry result, not featured evidence · combination
—140 mg BIW D1D2 + 960 mg QD
NCT05054725 · Phase 2 · registry result, not featured evidence · combination
Serious AEs
53.8%a
NCT04303780 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 3 more results
100%200 mg BIW D1D2 + 960 mg QD
NCT05054725 · Phase 2 · registry result, not featured evidence · combination
—200 mg D1D2 + 960 mg QD
NCT05054725 · Phase 2 · registry result, not featured evidence · combination
75%140 mg BIW D1D2 + 960 mg QD
NCT05054725 · Phase 2 · registry result, not featured evidence · combination
Most frequent reported AEs
a
diarrhoea 41.4%
nausea 25.4%
decreased appetite 23.1%
NCT04303780 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 2 more results
200 mg BIW D1D2 + 960 mg QD
diarrhoea 62.8%
alanine aminotransferase increased 46.5%
aspartate aminotransferase increased 44.2%
NCT05054725 · Phase 2 · registry result, not featured evidence · combination
140 mg BIW D1D2 + 960 mg QD
alanine aminotransferase increased 75%
aspartate aminotransferase increased 75%
diarrhoea 75%
NCT05054725 · Phase 2 · registry result, not featured evidence · combination

Notes

  1. aPopulation comparability has not been reviewed for 3 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Sotorasib

PFS 5.62 vs 4.47 Docetaxel months
time to event · months
NCT04303780 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
ORR 25.6% (n=43)200 mg BIW D1D2 + 960 mg QD
event count · % of participants
No placebo or comparator arm
NCT05054725 · Phase 2 · registry result, not featured evidence · combination · converted to % from 11 Participants as posted
show 1 more result
0% (n=4)*140 mg BIW D1D2 + 960 mg QD
NCT05054725 · Phase 2 · registry result, not featured evidence · combination · converted to % from 0 Participants as posted
Duration of Response 12.19 months200 mg BIW D1D2 + 960 mg QD
time to event · months
No placebo or comparator arm
NCT05054725 · Phase 2 · registry result, not featured evidence · combination
Disease Control 81% (n=42)200 mg BIW D1D2 + 960 mg QD
event count · % of participants
No placebo or comparator arm
NCT05054725 · Phase 2 · registry result, not featured evidence · combination · converted to % from 34 Participants as posted
show 1 more result
75% (n=4)*140 mg BIW D1D2 + 960 mg QD
NCT05054725 · Phase 2 · registry result, not featured evidence · combination · converted to % from 3 Participants as posted
PFS 7.66 months200 mg BIW D1D2 + 960 mg QD
time to event · months
No placebo or comparator arm
NCT05054725 · Phase 2 · registry result, not featured evidence · combination
show 1 more result
2.64 months140 mg BIW D1D2 + 960 mg QD
NCT05054725 · Phase 2 · registry result, not featured evidence · combination
Overall Survival 12.45 months200 mg BIW D1D2 + 960 mg QD
time to event · months
No placebo or comparator arm
NCT05054725 · Phase 2 · registry result, not featured evidence · combination
show 1 more result
5.8 months140 mg BIW D1D2 + 960 mg QD
NCT05054725 · Phase 2 · registry result, not featured evidence · combination

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Fulzerasib's landscape · Sotorasib's landscape